June 2023 ASCO update:

In a review of 8 clinical trials (N=513), immune checkpoint inhibitors (ICIs) including cemiplimab, pembrolizumab and nivolumab were effective in the treatment of resectable, locally-advanced, and metastatic cutaneous squamous cell carcinoma (cSCC).¹ ICIs were also shown to be safe and effective in the real-world cSCC setting, with patients showing response independent of age, comorbidities, or Eastern Cooperative Oncology Group (ECOG) performance status.² The NEO-CESQ study showed that neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cSCC induced a pathological response in 52% of the patients with a major pathological response rate of 48%.³

1. Anwar M, et al. Immune checkpoint inhibitors in cutaneous squamous cell carcinoma: a systematic review of clinical trials. J Clin Oncol. 2023;41(suppl 16); Abstract e21529.
2. Koch Hein EC, et al. Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: real-world evidence. J Clin Oncol. 2023;41(suppl 16); Abstract e21519.
3. Ascierto P, et al. NEO-CESQ study: neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma. J Clin Oncol. 2023;41(suppl 16); Abstract 9576.